Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIFF-Quick: Nasal Insulin Aspart in AD/MCI
NCT02462161Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2015
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) comparing Insulin Aspart with Placebo (2 arms). Primary endpoint: Change in cognition at 12 weeks. Started Mar 2015; status: completed.
02
Drugs
insulin aspart
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02462161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462161.